Vera Therapeutics (NASDAQ:VERA) Trading Down 6.4% – Here’s What Happened

Vera Therapeutics, Inc. (NASDAQ:VERA) fell 6.4% on Wednesday . The company traded as low as $31.96 and last traded at $31.5260. Approximately 1,337,920 shares changed hands during trading, a decline of 15% from the average daily volume of 1,568,487 shares. The stock had previously closed at $33.67.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: ORIGIN 3 met all prespecified endpoints. In the 428-patient final analysis, TRUTAKNA stabilized kidney function, producing a placebo-adjusted eGFR benefit of 5.6 mL/min/1.73m² at 52 weeks and a 5.0 mL/min/1.73m² annualized eGFR-slope benefit through 104 weeks. Vera Therapeutics ORIGIN 3 final analysis
• Positive Sentiment: Evidence of disease-modifying potential strengthened. Through two years, the treatment reduced the risk of a composite kidney-disease progression event by 76% versus placebo, with no TRUTAKNA patients experiencing dialysis, transplant, or death compared with eight placebo patients. Proteinuria, hematuria, and disease-related biomarkers also improved. STAT report on TRUTAKNA results
• Positive Sentiment: Regulatory and commercial catalysts are ahead. Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full approval, potentially in 2027. Management also reported more than 350 patient start forms during TRUTAKNA’s first ten weeks, along with early paid claims and encouraging payer policies. Yahoo Finance report on Vera shares
• Neutral Sentiment: Safety results were generally favorable, with overall adverse events and infections broadly comparable to placebo. However, TRUTAKNA remains approved under the accelerated-approval pathway, so continued approval depends on confirmation of clinical benefit and FDA review.
• Neutral Sentiment: Trading has been volatile. Shares initially rose on the trial news but later reversed, suggesting investors may be taking profits or awaiting detailed data, the supplemental BLA, and evidence that launch momentum converts into sustained revenue. Options activity also increased, reflecting heightened speculative interest. Benzinga report on VERA trading activity
• Negative Sentiment: Risks remain despite the positive trial. TRUTAKNA can increase infection risk and cause injection-site reactions, while full approval, market acceptance, payer coverage, and commercial execution are not guaranteed. Some analysts consequently maintained a more cautious view despite the clinical success. Seeking Alpha analysis of Vera Therapeutics

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Wedbush reaffirmed a “neutral” rating and set a $34.00 target price on shares of Vera Therapeutics in a research report on Monday, August 17th. Guggenheim upped their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $80.15.

Vera Therapeutics Trading Down 6.4%

The stock’s 50 day simple moving average is $34.80 and its two-hundred day simple moving average is $37.03. The stock has a market capitalization of $2.27 billion, a PE ratio of -5.38 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period in the previous year, the company posted ($1.20) earnings per share. On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -6.44 EPS for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total value of $649,720.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,261,769.28. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,250 shares of company stock valued at $3,307,800 over the last quarter. Corporate insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VERA. Engineers Gate Manager LP grew its position in Vera Therapeutics by 1,579.2% during the second quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock worth $4,640,000 after buying an additional 101,699 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Vera Therapeutics by 569.1% during the 2nd quarter. Squarepoint Ops LLC now owns 104,937 shares of the company’s stock valued at $4,503,000 after buying an additional 89,253 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Vera Therapeutics by 12.3% during the 2nd quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock worth $507,000 after acquiring an additional 1,295 shares during the last quarter. Nykredit A S purchased a new position in Vera Therapeutics in the second quarter worth $97,000. Finally, Readystate Asset Management LP purchased a new stake in Vera Therapeutics during the second quarter valued at about $12,663,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.